This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nupathe's Failure to Launch Leads to Modest Takeover

Nupathe (PATH) was granted U.S. approval for the migraine armband Zecuity last January but the company was never able to raise the money needed to launch the product commercially. 

On Monday, Endo Pharmaceuticals (ENDP - Get Report) acquired Nupathe at the fire-sale price of $2.85 per share. While that's a modest 24% premium to Nupathe's closing stock price on Friday, it's 25% lower than where Nupathe shares traded soon after Zecuity's approval last January. 

The all-cash acquisition will cost Endo $105 million.

Nupathe shareholders will be eligible for extra payments if Endo manages to turn Zecuity into a commercial success. A contingent value right (CVR) worth $2.15 per share will be paid out if Zecuity sales exceed $100 million during any four-quarter period within the first 9 years of commercial sales. The value of the CVR will rise to $3.15 if Zecuity sales exceed $300 million. 

Must Read: Ampio's Failed Drug Partner Talks Forces Spin-Out Plan

Zecuity is a battery-powered armband which delivers a dose of the generic migraine medicine sumatriptan through the skin. 

Endo shares were up 53 cents to $64.39 in early Monday trading. 

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PATH $0.00 0.00%
ENDP $60.52 0.40%
AAPL $118.32 -0.47%
FB $105.95 0.20%
GOOG $747.84 -0.06%


Chart of I:DJI
DOW 17,835.67 +23.48 0.13%
S&P 500 2,088.15 -0.99 -0.05%
NASDAQ 5,106.2780 +3.47 0.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs